Member Info for Stach

TWATCHR: post 9:29
You are out of date there and the AWARD of £374 mln is for Antigen Testing.This is far more reliable than Antibody testing and is more time consuming ,therefore more expensive.You also need more Staff to do huge number of tests.These tests are confirmatory tests that someone has indeed Covid-19.The AWARD was granted in May of 2021 2021.Stach

Thank you.I just clicked on "More like this" and under May Awards it clearly states that: " Manufacture of Lateral Antigen Tests for SARs'-2 Covid "
award: Omega Diagnostic £374 mln. This is an Official Confirmation of The Tender Award.If anybody was ever in charge of "tendering " process ,you will know that it is illegal to change your mind,after having seen what other Companies involved in the Tender have offered and on what conditions.
We just have to wait for the money transfer to OMEGA.We,all(reasonable posters here) know that OMEGA have increased Staff numbers by 250 to cope with an increased workload and the premises have also being enlarged.We shall get started in August,i am convinced of that.There is a need now more than ever for an extensive testing in All parts of UK by the end of August as schools will be opening then.ATB - Stach

The guy is steadily raising his stakes here increasing his potential value on the previous shots but we are creeping towards 4 billion shares in issue and the RNS states that there will be a further need to raise money again.I wonder how the Market will be responding to all this.By now we need a big Pharma(or someone like Welcome Trust) to conduct Clinical Trial as we have no chance to go it alone.Stach

Hi PHILBORO
Nice of you to notice.How are you? I am trying to top up my ISA to the full entitlement for this new financial year.Fed up with paying accountants' fees through other accounts.I have this strong feeling that at last SAR will deliver us (very,very lths') substantial gains for our loyalty to the Company.ATB - Stach

The share price is going up.Stach

Fannibaws
I just saw your post and gave it "Recommend".ATB-Stach

Thoth2
Who makes Remdesivir? It is not by a tiny research cell like SAR within Cambridge Lab.The cost of the drug,any drug is reflecting not only the research finding but,manufacture,distribution,sales force etc,etc..We are not a Pharma Company.What you are talking is profit that the drug makes world wide but not just for us,even if we are very successful.Stach

Hi potnak
Re your post at 11:22.Have punters considered how many shares are issued at the moment? We shall never be a Company of 3.5 billion pounds.It is just not realistic.I personally think that we have to many shares and (against my dislike of it) consolidation of shares right now I would accept,as it would reflect better what SAR is about.Stach

That 10:20:47 transaction was mine and is a "buy".We are now fairly close to finish Toxicology experiments and obtain the required data for the submission of CTA .The recent share price rises are going in right direction at last.GLA.Stach

Stoney40
Hi.When something is"tweaked" in the drug studies in the Lab,very often you have to repeat a lot of work that has been done already and that takes time.I also can tell you that it is not Tim himself that is doing the work.You only need couple of researches going off sick and you have a timing problem.In Covid situation ,as we have it now it is not easy to find somebody stepping in with replacement.Remember the Research Cells have usually very small number of Staff as compared with large Institutions or NHS.Another aspect is the manufacture and supply of the reagents/drugs,which again can derail your time scale.Just come down everybody.Stach

Ahfam3
Hello there.I gave you another "Recommend" for your last post.The living animal testing is in progress but hardly half way through.The testing (as planned) should finish at the end of June.Government's Grant was paid by January this year and was really needed in order to carry on this work.The results half way have to be analysed before any RNS of value can be issued and the Final analysis is even more important and time consuming so the submission of the CTA can only occur at best at the end of June.People here are totally unrealistic with their assumptions.I should be quite happy with the interim Report,half way through the testing,which is not to far now.Stach

citizen79...post 15:04 yesterday
Good morning.
A very good Post and I am not at all surprised that you have got so many "Recommends".You can go ad in finitum about the substrates the drugs are made off and their linking,the final value is that of how they behave biologically i.e in living environment.As our TYK-2 Inhibitor currently is being tried in living animals and it is not long for those tests to finish,the proof will be in the results that (we hope ) will propel our Compound into P-1 Clinical Trial.This is why I have increased my holding here recently.ATB-Stach

Hello AndytheMKDon andTjb68
I like your messages and like to add that swamping this BB with tons of scientific references is not doing very much good for 99% of posters here,who then are trying to put forward their own conclusions ,which have not as yet been tried in either animal testing or in the patients.There is a long way from cell lines testing to P1.Lab research is the start line but the healthy, live animal at the end of the tests is what usually Markets notice.Andy,you should remember how long we have been with CHK-1 Inhibitor till now.ATB - Stach

Hello PerryCherry
I am extremely reluctant to speculate on the magnitude of the share price either going up or down.The only time in my history of dealing on AIM that I have stack my neck out was indeed with SAR several years ago,when the share price was 0.8p/share and I felt that that was very undervalued as I knew from some of my colleagues in London presentation re CHK-1 Inhibitor work that they were up to something good.I suggested that it should be at least 1.6p/share and by the end of trading that day indeed happened and stayed there for some weeks.I have seen big rises 10 to 20 times on several different shares in my trading span.This is why AIM penny shares attract so many novices in share dealing.At present,you must remember that we have over 3 billion shares in issue and therefore personally I should be very happy if we end up anywhere between 8-12p/share.This is not written in Tablets of Stone by Stach, categorically! I wish you very Good Luck here.Stach

steve196...
Good morning.I think that there will be RNS a midway through anti TYK-2 study,which SAR hopes to finish before July.I am convinced that it is that that is propelling the share price right now.We are still considerably undervalued with regard as to the share price.Think back to last January when we were at 2.70p/share with nothing concrete to report.Now we have our teeth into serious RESEARCH supported by the Government just about half way through.With the success it will go into the Clinical Trial.Well,put the price on that.Stach

Well, I remember those 10 mice out of 10 been cured from leukaemia and the share price of SAR shifted quickly from 5 to11p/share and I have missed that shift! Ever since I promised myself not to be in same position ever again with SAR.The Company always collaborated with top researchers and doctors in UK(mainly based at Royal Marsden and CRUK) and hence the quality of the Research is always top class.This is why I have been invested here for many years.I can historcally say that the share price currently is well below par.Stach

Hello rv84.
Well,the highest was 2.7p in January and by now we are much closer to really important News for which not only we as shareholders are waiting but also The Government.They supported the idea with the Grant from public money.The share price should be very much higher than last January.Stach

Hello Ahfam.
You are correct,in order to prevent death from Covid,we need an effective treatment.Dexamethasone only good for less than 1/3 of all patients and there is a post-covid syndrome long term,which needs to be addressed.The vaccines are not 100% effective and in older and vulnerable patients antibodies levels fall back sooner than in younger patients.Whats' more,the peaks are also lower than in younger individuals.This is in the face of easy mutation makes things so much more difficult.Therefore both approaches of prevention and treatment is the way forward.SAR is in that latter group for now regarding the Research but who knows if the same future drug will not prevent developing symptoms of of viremia too. I think we are on the right track here with SAR.GL-Stach

That meagre 200k buy is mine this morning as a final ISA top up allowed.Soon will be able to add more next month.We are approaching mid point of Tyk-2 inhibitor study in animal testing and I think we should get an update.If it is a good one there may be another application for a further governmental Grant.I think SAR is a good play right now especially in view of what is happening on The Continent ie rampaging Covid-19 in spite of all previous preventative measures taken.ATB - Stach

Simon Potter is dangling another carrot but even the carrot looks plastic to most,normally thinking investors.What a mess has Koot drugged us into! There is nothing in BPC now and SP has an audacity labeling today's RNS "High Impact".The only high impact has (and is) been on shareholders pockets.I am beginning to think that Koot also knows that SAFFRON 1 is not what he expected to be and Goudron Sands were burying him in spite of all sorts of manipulation of the existing wells.I can not see any other reason why he went into the merger With BPC.He gambled and in a process gambled away our money as well.The RNS today gives not a clue what kind of hydrocarbons were found,at what depths,and how hard is surface covering them ie how possibly accessible they are.However SP is painting a new picture for sale whilst the old one will never be finished.I have had enough of these suckers and quit.ATB to many very decent people on this BB.Stach